Clusterin Inhibits MMP Enzymes for Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and dry eye disease are inadequate, with a lack of effective agents to inhibit Matrix Metalloproteinases (MMPs) such as MMP-2, MMP-9, and MMP-7, which are involved in tissue degradation and inflammation.
Innovation Solution
The identification of clusterin and its polypeptides that interact with and inhibit MMP-2, MMP-7, and MMP-9, providing a pharmaceutical composition for topical administration to treat inflammatory diseases and dry eye disease by reducing MMP activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for inflammatory diseases, then existing therapeutic options are available, but effective inhibition of MMP activity is insufficient
Solution Approach 1:
Clusterin acts as an intermediary substance that binds to and inhibits MMP enzymes (MMP-2, MMP-9, MMP-7). The patent identifies clusterin as a natural endogenous inhibitor that can be administered as a pharmaceutical composition to mediate the inhibition of MMP activity in inflammatory diseases and dry eye disease, providing a more effective therapeutic option than currently available treatments.
2Object-affected harmful factors
If MMP activity is not inhibited, then tissue degradation and inflammation progress, but effective therapeutic agents are lacking
Solution Approach 1:
The patent leverages clusterin, an endogenous protein already present in the body, as the therapeutic agent. By administering exogenous clusterin or clusterin-mimicking compounds, the treatment utilizes the body's own natural defense mechanism against MMP-mediated tissue degradation and inflammation, providing a reliable and biocompatible therapeutic approach.
Solution Approach 2:
Clusterin serves as a mediator that intervenes in the pathological process by binding to active MMP enzymes and inhibiting their proteolytic activity. This intermediary action directly addresses the harmful effects of uncontrolled MMP activity, including tissue degradation and inflammatory responses, offering effective protection when administered as a pharmaceutical composition.
Data Source
AI summary
Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.